US SEC Filing Intelligence

Defense Manufacturing Contracts — June 21, 2026

The single contract analyzed, a $1.26B award from the Department of Homeland Security (DHS) to Bollinger Shipyards Lockport, L.L.C., dominates the period and represents a significant civilian-agency defense procurement. This is a high-conviction, high-materiality signal for Bollinger, though the lack of pricing details and competition data introduces execution risk. The award underscores DHS's reliance on specialized shipyards for maritime security assets, a theme that benefits niche defense industrial base players. Key watch items include the contract's pricing structure (fixed-price vs. cost-plus) and whether this is a sole-source or competed award, which would materially alter the competitive moat assessment.

DHS Homeland Security Contracts — June 21, 2026

This single-day digest captures a single, highly material $1.26B Department of Homeland Security (DHS) contract awarded to Bollinger Shipyards Lockport, L.L.C. on December 19, 2025. Despite being classified under DHS, the contract is explicitly labeled as a defense contract, suggesting it supports a DHS mission with national security or military-adjacent applications, such as U.S. Coast Guard vessel construction. The award is 100% civilian-agency (DHS) with zero defense-related contracts in the period, but the $1.26B value and 7/10 signal strength make it the highest-conviction signal. Key risks include the lack of disclosed pricing structure (fixed-price vs. cost-plus) and competition details, which limit full risk assessment. Bollinger Shipyards is the sole beneficiary, creating a significant concentration risk for investors tracking DHS or defense shipbuilding exposure.

HHS & Healthcare Contracts Intelligence — June 21, 2026

This digest covers a single, massive $1.78B contract awarded to Leidos Biomedical Research Inc. by the Department of Health and Human Services (HHS), representing a purely civilian healthcare sector award with no defense exposure. The contract is a high-conviction bullish signal for Leidos, given its size relative to typical biomedical research awards, though the lack of pricing and competition details introduces execution and budget risk. The dominant theme is HHS's continued reliance on Leidos for large-scale biomedical research support, likely tied to the National Institutes of Health (NIH) mission. Key watch items include the contract's fixed-price vs. cost-plus structure and potential vulnerability to HHS budget reallocations or continuing resolution (CR) impacts in future fiscal years.

New Federal Contractors — June 21, 2026

Over a single day, June 21, 2026, two massive civilian-agency contracts totaling $3.04B were awarded, with zero defense-related obligations. The dominant theme is dual-use infrastructure: a $1.78B HHS contract to Leidos Biomedical Research for health/biodefense work, and a $1.26B DHS contract to Bollinger Shipyards for homeland security vessel construction. The highest-conviction signal is the sheer size and sole-source-like nature of both awards, suggesting deep incumbency or urgent mission need. A key risk is the lack of competition data—both awards may be sole-source or limited-competition, raising protest vulnerability and pricing opacity for investors.

Significant Contract Modifications ($10M+) — June 21, 2026

The two contracts analyzed, totaling $3.04 billion, are both classified as defense-related despite being awarded by civilian agencies—the Department of Health and Human Services (HHS) and the Department of Homeland Security (DHS)—highlighting a critical blurring of lines between civilian and defense spending. The dominant signal is a $1.78B award to Leidos Biomedical Research Inc. from HHS, representing the highest-conviction opportunity in the digest, while Bollinger Shipyards Lockport's $1.26B DHS contract underscores a separate maritime security theme. Both contracts carry bullish signals with a strong average signal strength of 7.0/10, but the absence of competitive or pricing data introduces execution and budget risks. Key watch items include potential continuing resolution (CR) impacts on HHS funding and DHS budget reauthorization timelines.

Contract Deobligations Alert — June 21, 2026

Over a single day on June 21, 2026, the government awarded $3.04B in total obligations, split entirely across civilian agencies (0% defense-related). The dominant theme is a massive $1.78B deobligation to Leidos Biomedical Research from HHS, paired with a $1.26B award to Bollinger Shipyards Lockport from DHS. Despite being labeled 'defense contracts' in the stream, both are civilian—Leidos supports biomedical research (likely NIH/NCI) and Bollinger builds Coast Guard vessels. The highest-conviction signal is the Leidos Biomedical award, which represents a material 58% of the aggregate and suggests sustained federal investment in health research infrastructure. A key risk is that both are deobligations (not new money), potentially indicating budget reallocations or contract closeouts rather than fresh spending, which could signal tightening civilian agency budgets.

Contract Option Exercises — June 21, 2026

The digest covers $3.04 billion in contract option exercises from June 21, 2026, split between two large awards, both classified as non-defense despite the agencies involved. The dominant theme is civilian agency spending, with the Department of Health and Human Services (HHS) accounting for $1.78 billion to Leidos Biomedical Research Inc. and the Department of Homeland Security (DHS) awarding $1.26 billion to Bollinger Shipyards Lockport, L.L.C. The highest-conviction signal is the sheer scale of the Leidos award, which represents a major biomedical research commitment. A key risk is the lack of pricing and competition details for both contracts, which obscures margin and protest risk.

All HHS Contracts — June 21, 2026

A single, massive $1.78B contract from the Department of Health and Human Services (HHS) to Leidos Biomedical Research Inc. dominates the period, representing 100% of the total obligation. This is a civilian agency award, not defense-related, and carries a bullish signal with high materiality (8/10). The contract's size suggests a critical, likely sole-source or follow-on award for biomedical research support, potentially tied to the National Cancer Institute or similar HHS entity. Key risks include execution risk given the large fixed-price or cost-plus nature (unknown pricing) and concentration risk for Leidos if this represents a significant portion of its revenue. Investors should watch for contract details (pricing type, competition status) and Leidos' upcoming earnings disclosures for revenue recognition guidance.

Mega Contracts Monitor ($100M+) — June 21, 2026

Over a single-day period, two mega-contracts totaling $3.04B were awarded, both classified as defense-related but originating from civilian agencies (HHS and DHS), highlighting a critical trend of non-DoD agencies driving defense-adjacent spending. Leidos Biomedical Research Inc. secured the largest award at $1.78B from HHS, signaling sustained biodefense and health security priorities. Bollinger Shipyards Lockport won a $1.26B DHS contract, reinforcing homeland maritime security investments. Both signals are bullish with high materiality, but the lack of competitive or pricing data introduces execution and budget risk, especially under potential Continuing Resolution constraints. The dominant theme is civilian-agency defense spending, with Leidos and Bollinger as the highest-conviction beneficiaries.

High-Value Federal Grants ($5M+) — June 21, 2026

The digest covers $3.04 billion in high-value federal obligations from June 21, 2026, split between two civilian-agency contracts with no defense-related awards. The dominant theme is large-scale, single-award contracts to niche contractors: Leidos Biomedical Research Inc. secured a $1.78B award from HHS, while Bollinger Shipyards Lockport won a $1.26B award from DHS. Both contracts carry bullish signals with high materiality, but the lack of competition data and unknown pricing structures introduce execution and budget risk. The highest-conviction signal is the sheer size of the Leidos Biomedical award, which suggests deep incumbency in health research support, though the absence of defense exposure limits sector-wide defense upside. Key watch items include potential protest risk on the Bollinger shipbuilding award and the impact of continuing resolutions on HHS funding for Leidos Biomedical.

General Federal Contracts — June 21, 2026

The two contracts analyzed total $3.04 billion, both classified as civilian awards despite being labeled 'defense' in the raw data. The Department of Health and Human Services (HHS) dominates with a $1.78B award to Leidos Biomedical Research Inc., while the Department of Homeland Security (DHS) contributes $1.26B to Bollinger Shipyards Lockport, L.L.C. The highest-conviction signal is the Leidos Biomedical award, which represents a massive, single-source obligation that could indicate a long-term operational contract. A key risk is the lack of pricing and competition data for both awards, which obscures margin and protest risk. The digest highlights a civilian agency spending surge but notes the absence of pure defense contracts, which may signal a shift in federal procurement focus away from DOD in this period.

Federal Construction & Infrastructure Contracts — June 20, 2026

This digest covers a single $126.8M civilian infrastructure contract awarded by the General Services Administration (GSA) to Ryan Companies US Inc for a new federal courthouse in Des Moines, IA. The contract is entirely civilian, with no defense exposure, and reflects stable GSA investment in federal building modernization. The fixed-price incentive pricing introduces moderate execution risk, though $84.4M has already been outlayed, reducing future funding uncertainty. The neutral signal strength (6/10) and full-and-open competition suggest a competitive win without a clear moat. Key watch items include margin performance on the incentive structure and potential option exercises for scope expansion.

New Federal Contractors — June 20, 2026

This digest covers four contracts totaling $550.5 million, all awarded by civilian agencies (0% defense-related), with no single contractor receiving multiple awards. The dominant theme is stable, long-duration civilian IT and professional services: Booz Allen Hamilton ($142.9M) and Accenture Federal Services ($141.7M) both secured large CMS and State Department contracts, respectively, providing multi-year revenue visibility. The highest-conviction signal is Booz Allen’s firm-fixed-price CMS win, which represents a durable, competitive win in a stable federal program evaluation market. Key risks include cost-plus pricing suppressing margins at Accenture and potential budget uncertainty for NASA science programs following the PUNCH contract’s upcoming expiry in 2027. With an average signal strength of 5.8/10, this batch offers modest investment insight, weighted toward civilian IT services stability rather than transformative defense growth.

Significant Contract Modifications ($10M+) — June 20, 2026

This digest covers $550.5 million in significant contract modifications from June 20, 2026, all civilian agency awards with zero defense exposure, reflecting a notable divergence from typical DOD-heavy procurement flows. The dominant theme is stable, multi-year civilian IT and infrastructure spending, with Booz Allen Hamilton's $142.9M CMS PERM contract and Accenture Federal Services' $141.7M State Department data replication award representing the highest-conviction signals for long-term revenue visibility. However, the neutral-to-moderate signal strength (avg 5.8/10) and cost-plus pricing on two of the four contracts temper margin optimism. Key risk: only $41.5M of Accenture's $141.7M obligation has been outlayed, signaling potential funding phasing or execution delays that could pressure near-term cash flows for Novetta Solutions LLC's subsidiary. Investors should monitor CMS budget continuity for the PERM program and NASA's PUNCH mission milestones as catalysts for follow-on awards.

Contract Deobligations Alert — June 20, 2026

The four contracts analyzed total $550.5 million in obligations, all from civilian agencies, with zero defense-related awards. The dominant theme is civilian IT and infrastructure spending, led by a $142.9M Booz Allen Hamilton contract with CMS for program evaluation (bullish, 7/10 signal strength) and a $141.7M Accenture Federal Services award from the State Department for data replication services. The highest-conviction signal is Booz Allen's long-term revenue visibility through 2028, while key risks include the fixed-price incentive structure on the $126.8M Ryan Companies courthouse contract and the cost-plus pricing on Accenture's award limiting margin upside.

Contract Option Exercises — June 20, 2026

This digest covers four civilian agency contract option exercises totaling $550.5 million, with zero defense-related awards, underscoring a non-defense procurement focus. The dominant theme is stable, multi-year civilian IT and infrastructure spending, led by a $142.9M CMS award to Booz Allen Hamilton (the sole bullish signal) and a $141.7M State Department data replication contract to Accenture Federal Services. A $139.2M NASA space science contract with Southwest Research Institute and a $126.8M GSA courthouse construction award to Ryan Companies US Inc complete the set. The highest-conviction signal is Booz Allen's competitive win at CMS, providing long-term revenue visibility through 2028. Key risks include margin pressure on Ryan Companies' fixed-price incentive courthouse contract and the phased funding profile of Accenture's cost-plus award.

Federal Professional Services Contracts — June 20, 2026

The two contracts analyzed total $282.0M in obligations, both from civilian agencies (0% defense), with an average signal strength of 6.0/10. The dominant theme is stable, long-duration civilian professional services, led by a $142.9M Booz Allen Hamilton award from HHS/CMS for program evaluation through 2028, which is the highest-conviction bullish signal. The second award, a $139.2M NASA contract to Southwest Research Institute for space instrumentation, is neutral due to cost-plus pricing and nonprofit status limiting margin upside. Key risks include medium pricing risk on Booz Allen's fixed-price contract and potential budget uncertainty for CMS's PERM program.

Federal IT & Cybersecurity Contracts — June 20, 2026

The single contract in this digest, a $141.7 million cost-plus-award-fee delivery order awarded to Accenture Federal Services LLC by the Department of State, represents a pure civilian IT services win with no defense exposure. The contract is for data replication engineering and management support through September 2026, but only $41.5 million has been outlayed as of the award date, signaling potential funding phasing or early-stage performance risk. The neutral signal (strength 5/10, materiality 4/10) and low pricing risk suggest a stable but unexciting revenue stream for Accenture Federal Services, with limited upside margin potential due to the cost-plus structure. Key watch items include the outlay rate and any contract modifications near the September 2026 end date.

All HHS Contracts — June 20, 2026

This digest covers a single, large civilian contract from the Department of Health and Human Services (HHS) to Booz Allen Hamilton Inc., valued at $142.9 million. The award is a firm-fixed-price delivery order under the CMS PERM program, with no defense-related exposure. The highest-conviction signal is bullish, reflecting multi-year revenue visibility through 2028 and a competitive win against peers. Key risks include medium pricing risk on a fixed-price contract and potential budget uncertainty for CMS program integrity funding under a Continuing Resolution. The contract reinforces Booz Allen's strong position in federal health program evaluation services, a stable civilian sector niche.